SPRY
ARS Pharmaceuticals, Inc.Company Information
- Company Name
- ARS Pharmaceuticals, Inc.
- CIK
- CIK0001671858
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SPRY: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SPRY
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-03-27
- Last sale
- 2026-06-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,086,868
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 88,699,239
- Shares outstanding
- 99,312,526
- Ownership
- 89.31%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -7.87%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 24 | 41 | 60 | 52 | 40 | 51 | 40 | 37 | 56 | 71 | 61 | ||||||
| Short Term Investments | 136 | 177 | 204 | 229 | 189 | 236 | 263 | 165 | 182 | 168 | 157 | 181 | ||||||
| Accounts Receivable Net Current | 47 | 29 | 25 | 36 | 25 | 9 | 8 | 1 | - | - | 0 | - | ||||||
| Inventory Net | - | - | 31 | - | - | 7 | 11 | 1 | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 7 | 6 | 6 | 7 | 12 | 7 | 3 | 2 | 3 | 3 | 3 | ||||||
| Assets Current | 212 | 245 | 285 | 339 | 281 | 304 | 334 | 209 | 221 | 226 | 232 | 244 | ||||||
| Inventory Noncurrent | 19 | 23 | 23 | 14 | 13 | 12 | 5 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | - | - | - | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 14 | 14 | 14 | 15 | 13 | 7 | 7 | 8 | - | - | 0 | - | ||||||
| Other Assets | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 1 | 1 | 3 | ||||||
| Assets | 249 | 288 | 328 | 373 | 313 | 327 | 351 | 218 | 222 | 228 | 233 | 249 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 60 | 48 | 38 | 50 | 44 | 27 | 23 | 17 | 7 | 3 | 2 | 11 | ||||||
| Contract With Customer Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Current | - | - | - | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 61 | 50 | 39 | 51 | 46 | 28 | 23 | 17 | 7 | 4 | 2 | 11 | ||||||
| Long Term Debt | 97 | 97 | 96 | 96 | - | - | 0 | - | - | - | - | - | ||||||
| Contract With Customer Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 2 | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | 1 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Accrued Liabilities Noncurrent | 3 | 4 | 5 | 4 | 1 | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 237 | 226 | 213 | 225 | 121 | 98 | 94 | 17 | 7 | 4 | 2 | 11 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 430 | 417 | 409 | 401 | 394 | 386 | 380 | 374 | 369 | 366 | 362 | 362 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -418 | -355 | -295 | -253 | -202 | -157 | -123 | -173 | -154 | -142 | -131 | -124 | ||||||
| Stockholders Equity | 13 | 61 | 114 | 148 | 192 | 229 | 257 | 201 | 215 | 224 | 231 | 237 | ||||||
| Liabilities And Stockholders Equity | 249 | 288 | 328 | 373 | 313 | 327 | 351 | 218 | 222 | 228 | 233 | 249 | ||||||
| Other Receivables Net Current | - | - | - | 4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Related Party Deposit Liabilities | 5 | 5 | 5 | 5 | - | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 99 | 99 | 99 | 99 | 99 | 98 | 98 | 97 | 97 | 97 | 96 | 96 | ||||||
| Shares Outstanding | 99 | 99 | 99 | 99 | 99 | 98 | 98 | 97 | 97 | 97 | 96 | 96 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialARS Pharmaceuticals, Inc. (SPRY) — SEC Financial Statements & Analysis
ARS Pharmaceuticals, Inc. (SPRY) is a pharmaceutical preparations company, incorporated in DE. ARS Pharmaceuticals, Inc. trades on Nasdaq as: SPRY. ARS Pharmaceuticals, Inc. (SPRY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, ARS Pharmaceuticals, Inc. carries a market cap of $795.49M, a P/E ratio of -3.69x, a P/B ratio of 63.58x, a P/S ratio of 6.80x, an enterprise value of $884.01M, and an EV/EBITDA multiple of -4.12x. On profitability, it posts a gross margin of 94.43%, an operating margin of -184.96%, a net margin of -184.24%, a Return on Equity (ROE) of -210.35%, a Return on Assets (ROA) of -76.53%, and a Return on Invested Capital (ROIC) of -175.55%. Per share, it reports EPS of $-2.17, diluted EPS of $-2.17, free cash flow per share of $-1.98, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 4.08% year-over-year, net income growth of 348.66% year-over-year, and EPS growth of 344.36% year-over-year. On the balance sheet, it maintains a current ratio of 3.48x, a quick ratio of 3.33x, working capital of $150.65M, a debt-to-equity ratio of 18.94x, a debt ratio of 0.95, free cash flow of $-196.60M (TTM), and net debt of $88.51M. Figures sourced from SEC EDGAR.
- Market Cap
- $795.49M
- P/E TTM
- -3.69x
- EPS TTM
- $-2.17
- P/B TTM
- 63.58x
- ROE TTM
- -210.35%
- ROA TTM
- -76.53%
- Debt To Equity
- 18.94x
- Free Cash Flow TTM
- $-196.60M
- Net Revenue TTM Growth 1Y
- 4.08%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ARS Pharmaceuticals, Inc. in?
ARS Pharmaceuticals, Inc. (SPRY) operates in the Pharmaceutical Preparations industry.
What exchange does SPRY trade on?
ARS Pharmaceuticals, Inc. (SPRY) trades on the Nasdaq.
Where is ARS Pharmaceuticals, Inc. incorporated?
ARS Pharmaceuticals, Inc. is incorporated in DE.
When was ARS Pharmaceuticals, Inc. (SPRY)'s most recent SEC filing?
ARS Pharmaceuticals, Inc. (SPRY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is SPRY's market cap?
ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $795.49M as of 2026-06-30.
What is SPRY's EPS (earnings per share)?
ARS Pharmaceuticals, Inc. (SPRY)'s trailing twelve month EPS is $-2.17 as of 2026-06-30.
What is SPRY's ROE (return on equity)?
ARS Pharmaceuticals, Inc. (SPRY)'s trailing twelve month Return on Equity (ROE) is -210.35% as of 2026-06-30.
What is SPRY's ROA (return on assets)?
ARS Pharmaceuticals, Inc. (SPRY)'s trailing twelve month Return on Assets (ROA) is -76.53% as of 2026-06-30.
What is SPRY's ROIC (return on invested capital)?
ARS Pharmaceuticals, Inc. (SPRY)'s trailing twelve month Return on Invested Capital (ROIC) is -175.55% as of 2026-06-30.
What is SPRY's EV/EBITDA?
ARS Pharmaceuticals, Inc. (SPRY)'s trailing twelve month EV/EBITDA is -4.12x as of 2026-06-30.